Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis
Blood · 2023
DOI: 10.1182/blood.2022017097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Sara Lecomte und 13 weiteren Autor:innen. Beteiligte Einrichtung: de Duve Institute, Université catholique de Louvain, Brussels, Belgium. Hauptthemen laut MEDLINE: Transforming Growth Factor beta1, Primary Myelofibrosis. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by the clonal expansion of myeloid cells, notably megakaryocytes (MKs), and an aberrant cytokine production leading to bone marrow (BM) fibrosis and insufficiency. Current treatment options are limited. TGF-β1, a profibrotic and immunosuppressive cytokine, is involved in PMF pathogenesis. While all cell types secrete inactive, latent TGF-β1, only a few activate the cytokine via cell type–specific mechanisms. The cellular source of the active TGF-β1 implicated in PMF is not known. Transmembrane protein GARP binds and activates latent TGF-β1 on the surface of regulatory T lymphocytes (Tregs) and MKs or platelets. Here, we found an increased expression of GARP in the BM and spleen of mice with PMF and tested the therapeutic potential of a monoclonal antibody (mAb) that blocks TGF-β1 activation by GARP-expressing cells. GARP:TGF-β1 blockade reduced not only fibrosis but also the clonal expansion of transformed cells. Using mice carrying a genetic deletion of Garp in either Tregs or MKs, we found that the therapeutic effects of GARP:TGF-β1 blockade in PMF imply targeting GARP on Tregs. These therapeutic effects, accompanied by increased IFN-γ signals in the spleen, were lost upon CD8 T-cell depletion. Our results suggest that the selective blockade of TGF-β1 activation by GARP-expressing Tregs increases a CD8 T-cell-mediated immune reaction that limits transformed cell expansion, providing a novel approach that could be tested to treat patients with myeloproliferative neoplasms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- de Duve Institute, Université catholique de Louvain, Brussels, Belgium.
- Department of Hematology, Cliniques universitaires Saint-Luc, Brussels, Belgium.
- Ludwig Institute for Cancer Research Brussels, Brussels, Belgium.
- Walloon Excellence in Life Sciences and Biotechnology, Wavre, Belgium.
- Nuffield Department of Medicine, Ludwig Institute for Cancer Research Oxford, University of Oxford, Oxford, United Kingdom.
ORCID-Profile: Julien Devreux, Grégoire de Streel, Nicolas van Baren, David Schröder, Christophe Vanderaa, Christian Pecquet, Stefan N Constantinescu, Sophie Lucas
Zitieren
APA
Lecomte, S., Devreux, J., de Streel, G., van Baren, N., Havelange, V., Schröder, D., Vaherto, N., Vanhaver, C., Vanderaa, C., Dupuis, N., Pecquet, C., Coulie, P. G., Constantinescu, S. N., & Lucas, S. (2023). Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis. Blood. https://doi.org/10.1182/blood.2022017097
Vancouver
Lecomte S, Devreux J, de Streel G, van Baren N, Havelange V, Schröder D, et al. Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis. Blood. 2023. doi:10.1182/blood.2022017097
BibTeX
@article{Lecomte2023,
author = {Lecomte, Sara and Devreux, Julien and de Streel, Grégoire and van Baren, Nicolas and Havelange, Violaine and Schröder, David and Vaherto, Noora and Vanhaver, Christophe and Vanderaa, Christophe and Dupuis, Noémie and Pecquet, Christian and Coulie, Pierre G and Constantinescu, Stefan N and Lucas, Sophie},
title = {Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022017097}
}
EUVIMED